![]() |
Volumn 74, Issue 2-3, 2000, Pages 135-140
|
Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: Characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors
a a a a a a a a a a a a a |
Author keywords
Alzheimer's disease; CDD 0102; Memory function; Molecular modeling; Muscarinic receptor; Site directed mutagenesis; Xanomeline
|
Indexed keywords
5 (3 ETHYL 1,2,4 OXADIAZOL 5 YL) 1,4,5.6 TETRAHYDROPYRIMIDINE TRIFLUOROACETIC ACID;
CDD 0102;
MUSCARINIC AGENT;
MUSCARINIC M1 RECEPTOR;
TETRAHYDROPYRIMIDINE DERIVATIVE;
UNCLASSIFIED DRUG;
XANOMELINE;
ALZHEIMER DISEASE;
ANIMAL MODEL;
BINDING AFFINITY;
BRAIN INJURY;
CELL LINE;
CHOLINERGIC SYSTEM;
CONFERENCE PAPER;
CONTROLLED STUDY;
DRUG DESIGN;
DRUG DEVELOPMENT;
DRUG RECEPTOR BINDING;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
MEMORY;
MOLECULAR MODEL;
MOUSE;
NONHUMAN;
RAT;
STRUCTURE ACTIVITY RELATION;
ALZHEIMER DISEASE;
ANIMALS;
DRUG DESIGN;
INJECTIONS, INTRAPERITONEAL;
LIGANDS;
MALE;
MODELS, MOLECULAR;
MUSCARINIC AGONISTS;
MUTAGENESIS, SITE-DIRECTED;
PYRIDINES;
RATS;
RATS, SPRAGUE-DAWLEY;
RECEPTOR, MUSCARINIC M1;
RECEPTORS, MUSCARINIC;
THIADIAZOLES;
|
EID: 0343294314
PISSN: 00316865
EISSN: None
Source Type: Journal
DOI: 10.1016/S0031-6865(99)00026-6 Document Type: Article |
Times cited : (27)
|
References (25)
|